AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19376787
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg(‐1)
Trial: 14675064
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of zoledronic acid (ZOL)
Trial: 2576364
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg o.d.)
Trial: 7980837
Drug: Cassava-salt suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cassava-salt suspension (CSS)
Trial: 2510271
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg nocte
Trial: 1205340
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of heparin
Trial: 1157717
Drug: Calcium heparinate
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparinate (conventional high doses)
Trial: 29861395
Drug: CBDCA with
RxNorm normalized name: CBDCA
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CBDCA with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15 of each 21-day cycle)
Trial: 29861395
Drug: DOC (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOC (60 mg/m2 intravenous [I.V.] on day 1)
Trial: 23107038
Drug: Combination exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination exercise training
Trial: 20301021
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) - sirolimus-eluting stents (SES)
Trial: 27245042
Drug: Nifedipine sustained-release
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine sustained-release tablets
Trial: 2664571
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg i.v./i.m. b.i.d., starting the day before the surgery for 8 days)
Trial: 25807090
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 mg daily for 14 days, then 200 mg daily for 14 days)
Trial: 21344260
Drug: Acetaminophen 2
RxNorm normalized name: acetaminophen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 2 g intravenously 30 min before surgery
Trial: 14689227
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of contrast material (CM) at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s
Trial: 11870505
Drug: Cisplatin suspension
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin suspension (5 mg in 1 ml, 150 mg m(‐2), max 300 mg, max fluid 60 ml)
Trial: 11870505
Drug: Usual cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual cisplatin solution (150 mg m(‐2) dissolved in 500 ml saline)
Trial: 8031162
Drug: 5-FU tablets
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU tablets administered at a dose of 200 mg/day for 6 months
Trial: 8031162
Drug: Surgery alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery alone (no chemotherapy)
Trial: 1832291
Drug: xipamide 20
RxNorm normalized name: xipamide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xipamide 20 mg once daily
Trial: 25970485
Drug: Combined hyperbaric
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hyperbaric (4 mg) and hypobaric (6 mg) ropivacaine (Group A)
Trial: 23108937
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg, then 150 mg)
Trial: 21736751
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg SC every 4 weeks
Trial: 21736751
Drug: Canakinumab 300
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 300 mg SC every 2 weeks
Trial: 16401655
Drug: Promethazine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 30 mg (P30)
Trial: 2070977
Drug: Injection sclerosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerosis
Trial: 9283858
Drug: Medical-surgical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical-surgical treatment
Trial: 27484507
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training loaded with 40% of maximum inspiratory pressure, readjusted weekly
Trial: 22568863
Drug: GSK1482160 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1482160 (up to 1 g, single doses)
Trial: 19246793
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (400 IU twice daily)
Trial: 19246793
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard therapy only)
Trial: 15719740
Drug: Shentao Ruangan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shentao Ruangan pill (SRP) combined with local perfusion of hydroxycamptothecine (HCPT)
Trial: 12949315
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension 0.5 mg (total daily dose) once or twice daily
Trial: 12949315
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium nebulizer solution 20 mg 4 times daily
Trial: 11986448
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension
Trial: 16113791
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (0.8 mg/day) for 1 year
Trial: 1850344
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.6 mg/kg/day)
Trial: 31008987
Drug: Novel circumcision
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel circumcision method (subcutaneous tissue-sparing dorsal slit with new marking)
Trial: 26116491
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment - High-Viscosity Glass-Ionomer Cement (ART-GIC)
Trial: 21052775
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h followed by radiotherapy and adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Trial: 2081789
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% albumin-normal saline, 10 ml/kg)
Trial: 6986007
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg oxatomide b.i.d.
Trial: 31752042
Drug: Routine GPI
RxNorm normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine GPI administration before primary PCI
Trial: 31752042
Drug: Bailout GPI
RxNorm normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bailout GPI administration
Trial: 31752042
Drug: Routine GPI
RxNorm normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine GPI administration
Trial: 30730541
Drug: rAAV2/2-ND4 (9×109,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2/2-ND4 (9×109, 3×1010, 9×1010, and 1.8×1011 viral genomes per eye) as a single unilateral intravitreal injection
Trial: 28760390
Drug: Cigarettes (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes (CC)
Trial: 25047652
Drug: Electrodiagnostic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrodiagnostic testing with physical therapy (specific interventions not detailed)
Trial: 16221926
Drug: Cabergoline (DA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (DA agonist)
Trial: 21544070
Drug: Methylphenidate (indirect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (indirect NE agonist)
Trial: 19039224
Drug: dose fractionation
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose fractionation
Trial: 15205602
Drug: Intratumoral (i.t.)
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral (i.t.) administration of cisplatin
Trial: 27860389
Drug: Canrenone 50
RxNorm normalized name: canrenone
DrugBank: Canrenone (DB12221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenone 50 mg
Trial: 19329547
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg LDX
Trial: 9447858
Drug: High-dose ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ondansetron (150 microg/kg)
Trial: 2243152
Drug: Diphenhydramine hydrochloride
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine hydrochloride 12.5 mg
Trial: 2243152
Drug: Diphenhydramine hydrochloride
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine hydrochloride 25 mg
Trial: 8634878
Drug: Diphenhydramine hydrochloride
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine hydrochloride 50 mg
Trial: 2243152
Drug: Diphenhydramine hydrochloride
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine hydrochloride (all doses)
Trial: 23453899
Drug: Low dose,
RxNorm normalized name: Aspirin Low Dose, 81 mg oral tablet, chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose, metronomic cyclophosphamide + methotrexate (CM)
Trial: 15356567
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg once daily (monotherapy)
Trial: 15356567
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg once daily plus Montelukast 10 mg once daily (combined therapy)
Trial: 15356567
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily (monotherapy)
Trial: 28433798
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 250 IU/kg daily during the first 6 days of life
Trial: 21971473
Drug: Cognitive intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive intervention groups (IGs) receiving weekly sessions of group‐based multicomponent cognitive intervention
Trial: 22516441
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg daily
Trial: 14963471
Drug: PT-141 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT-141 (doses greater than 7 mg)
Trial: 11898004
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment
Trial: 31637444
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy plus intrathecal liposomal cytarabine (median 5 injections, range 1-20)
Trial: 31637444
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy alone (control group)
Trial: 31637444
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy plus intrathecal liposomal cytarabine
Trial: 10527996
Drug: Trimegestone-based sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone-based sequential hormone replacement therapy (HRT) with doses of 0.05, 0.1, 0.25, and 0.5 mg per day of trimegestone from day 15 to day 28, combined with continuous micronized oestradiol 2 mg daily for six treatment cycles
Trial: 7579312
Drug: Regimen 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1: rifampicin, isoniazid and pyrazinamide daily for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Trial: 7579312
Drug: Regimen 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 2: rifampicin, isoniazid and pyrazinamide thrice‐weekly for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Trial: 15113269
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg
Trial: 7272160
Drug: Oxprenolol 80
RxNorm normalized name: oxprenolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 80 mg
Trial: 7138753
Drug: Oxprenolol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (twice a day for 2 weeks)
Trial: 24420556
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and etoposide plus concurrent and sequential sorafenib 200 mg orally bid for four cycles, then 400 mg orally bid as maintenance for up to 12 months after no disease progression.
Trial: 24420556
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and etoposide plus concurrent and sequential sorafenib.
Trial: 3221375
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil 240 mg tablets
Trial: 30786304
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg of dipyrone
Trial: 19691426
Drug: Sitagliptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 200 mg once daily
Trial: 14612477
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg oral at 24 hours and 1-2 hours before TKA, 50 mg daily for 5 days postoperatively, and 25 mg daily for another 8 days)
Trial: 9122013
Drug: Antibiotics therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics therapy
Trial: 1812424
Drug: Meningococcal outer
RxNorm normalized name: Haemophilus Influenzae Type B Capsular Polysaccharide Meningococcal Outer Membrane Protein Conjugate antigen
DrugBank: Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (DB10342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal outer membrane vesicle serogroup B vaccine (MenB‐vaccine "Folkehelsa")
Trial: 6615664
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg twice daily for five days)
Trial: 26345529
Drug: Respiratory rehabilitation
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory rehabilitation exercise training (twice a day, 10-30 minutes per session for 4 days)
Trial: 16950948
Drug: Spring dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spring dosing schedule of trivalent inactivated influenza vaccine
Trial: 16950948
Drug: Fall dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fall dosing schedule of trivalent inactivated influenza vaccine
Trial: 11319653
Drug: Sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10 mg/day)
Trial: 19368098
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification plus combinations of insulin sensitisers and insulin secretagogues
Trial: 19368098
Drug: Incretin mimetics
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin mimetics or insulin
Trial: 8857005
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of hCG (250, 500, 1000, or 2000 IU) three times a week for two weeks.
Trial: 8857005
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of hCG.
Trial: 8730980
Drug: Benzhexol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzhexol (5 mg)
Trial: 8379601
Drug: Caffeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg)
Trial: 16142502
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 or 40 mcg/day)
Trial: 17013567
Drug: Teriparatide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (40 mcg/day)
Trial: 15302288
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day
Trial: 15823826
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day
Trial: 15823826
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 5.0 mg/day
Trial: 7472662
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid supplementation (10 g/d from the 20th week of gestation until delivery)
Trial: 2318517
Drug: Second drug
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second drug (hydralazine, methyldopa, metoprolol, or reserpine) added to hydrochlorothiazide
Trial: 23694801
Drug: 1+1 hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1+1 hydromorphone titration protocol
Trial: 8276647
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rate brachytherapy
Trial: 8276647
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate brachytherapy
Trial: 656283
Drug: Cholestyramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine treatment (about 4 g three times daily)
Trial: 24491267
Drug: Chemoradiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy plus 3,500 IU daily of bemiparin for a maximum of 26 weeks
Trial: 17523385
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with Betulaceae extracts
Trial: 30589965
Drug: Vonoprazan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan (20 mg daily)
Trial: 28680717
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg daily)
Trial: 25773009
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose multivitamin and mineral supplement (1× RDI for 30 days, then 2× RDI for 30 days)
Trial: 23447043
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of indapamide
Trial: 23447043
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of indapamide
Trial: 20872082
Drug: Adverse Drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse Drug Events (ADEs)
Trial: 20872082
Drug: Medication Errors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Errors
Trial: 19576324
Drug: ERN/LRPT (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT (1 g for 4 weeks advanced to 2 g for 12 weeks)
Trial: 17054812
Drug: 6% HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 130/0.42 with balanced crystalloid solution (Group A)
Trial: 17054812
Drug: Conventional HES
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional HES 130/0.42 plus unbalanced crystalloid (saline solution) (Group B)
Trial: 11838060
Drug: Implantation group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation group (20 patients) - implanted with compound artificial bone of HA‐Bone cement
Trial: 9565283
Drug: Magnetized water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetized water oral irrigator